- RON1.62bn
- RON1.76bn
- RON675.01m
- 75
- 43
- 16
- 37
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.8 | ||
| Price to Tang. Book | 1.92 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.4 | ||
| EV to EBITDA | 11.54 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.24% | ||
| Return on Equity | 11.4% | ||
| Operating Margin | 15.94% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | RONm | 340.42 | 366.21 | 482.67 | 600.78 | 675.01 | n/a | n/a | 11.61% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -14.38 | +13.46 | +28.63 | +113.89 | +20.68 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Antibiotice SA is a Romania-based company primarily active in the pharmaceutical industry. The Company manufactures drugs in five pharmaceutical forms: powder for injectable solutions and suspensions, capsules, tablets, suppositories and preparations. The Company's products are designed to treat a range of diseases, including infectious, dermatology, cardiovascular, digestive and musculoskeletal system related. The Company operates eight certified production lines. Its portfolio includes products for human and veterinary use, pharmaceutical ingredients and biological fertilizers. Additionally, the Company is engaged in the research and development activities.
Directors
- Lucian Timofticiuc CHM
- Ioan Nani CEO (59)
- Paula Coman CFO (51)
- Cornelia Moraru CTO (53)
- Eugen Osadet CIN (64)
- Cristina Diaconescu VRD (51)
- Ovidiu Bataga DSL (41)
- Delia Racoveanu DSL (47)
- Vasile Chebac DSL (64)
- Gica Rusu DHR (56)
- Cristina Dimitriu OTH (62)
- Mihaela Mosnegutu OTH (49)
- Mihaiela Stoenescu OTH (51)
- Mihai Stoian OTH (43)
- Dan Alexandrescu NED (44)
- Elena Calitoiu NED (58)
- Cristian Grasu NED
- Adela Neagoe NED (60)
- Nicolae Stoian NED (62)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 15th, 1991
- Public Since
- April 16th, 1997
- No. of Employees
- 1,352
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Bucharest Stock Exchange- Shares in Issue
- 671,338,040
- Address
- str. Valea Lupului nr.1, IASI, 707410
- Web
- https://www.antibiotice.ro/
- Phone
- +40 232209000
- Contact
- Cerasela Moraru
- Auditors
- SOCECC SRL
Upcoming Events for ATB
Similar to ATB
Biofarm SA
Bucharest Stock Exchange
Zentiva SA
Bucharest Stock Exchange
FAQ
As of Today at 18:17 UTC, shares in Antibiotice SA are trading at RON2.41. This share price information is delayed by 15 minutes.
Shares in Antibiotice SA last closed at RON2.41 and the price had moved by +49.38% over the past 365 days. In terms of relative price strength the Antibiotice SA share price has outperformed the FTSE Global All Cap Index by +35.18% over the past year.
There is no consensus recommendation for this security.
Find out moreAntibiotice SA does not currently pay a dividend.
Antibiotice SA does not currently pay a dividend.
Antibiotice SA does not currently pay a dividend.
To buy shares in Antibiotice SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of RON2.41, shares in Antibiotice SA had a market capitalisation of RON1.62bn.
Here are the trading details for Antibiotice SA:
- Country of listing: Romania
- Exchange: BUH
- Ticker Symbol: ATB
Based on an overall assessment of its quality, value and momentum Antibiotice SA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Antibiotice SA is RON2.00. That is 17.01% below the last closing price of RON2.41.
Analysts covering Antibiotice SA currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Antibiotice SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -24%.
As of the last closing price of RON2.41, shares in Antibiotice SA were trading -13.76% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Antibiotice SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at RON2.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Antibiotice SA's management team is headed by:
- Lucian Timofticiuc - CHM
- Ioan Nani - CEO
- Paula Coman - CFO
- Cornelia Moraru - CTO
- Eugen Osadet - CIN
- Cristina Diaconescu - VRD
- Ovidiu Bataga - DSL
- Delia Racoveanu - DSL
- Vasile Chebac - DSL
- Gica Rusu - DHR
- Cristina Dimitriu - OTH
- Mihaela Mosnegutu - OTH
- Mihaiela Stoenescu - OTH
- Mihai Stoian - OTH
- Dan Alexandrescu - NED
- Elena Calitoiu - NED
- Cristian Grasu - NED
- Adela Neagoe - NED
- Nicolae Stoian - NED